RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.

Viziteu, E; Klein, B; Basbous, J; Lin, Y-L; Hirtz, C; Gourzones, C; Tiers, L; Bruyer, A; Vincent, L; Grandmougin, C; Seckinger, A; Goldschmidt, H; Constantinou, A; Pasero, P; Hose, D; Moreaux, J

Viziteu, E; Klein, B; Basbous, J; Lin, Y-L; Hirtz, C; Gourzones, C; Tiers, L; Bruyer, A; Vincent, L; Grandmougin, C; Seckinger, A; Goldschmidt, H; Constantinou, A; Pasero, P; Hose, D; Moreaux, J.

Afiliación

Viziteu E; Institute of Human Genetics, UMR 9002, CNRS and University of Montpellier, Montpellier, France.
Klein B; Institute of Human Genetics, UMR 9002, CNRS and University of Montpellier, Montpellier, France.
Basbous J; Department of Biological Hematology, CHU Montpellier, Montpellier, France.
Lin YL; University of Montpellier, UFR de Médecine, Montpellier, France.
Hirtz C; Institute of Human Genetics, UMR 9002, CNRS and University of Montpellier, Montpellier, France.
Gourzones C; Institute of Human Genetics, UMR 9002, CNRS and University of Montpellier, Montpellier, France.
Tiers L; Clinical Proteomic Platform, CHU Montpellier, Montpellier, France.
Bruyer A; Institute of Human Genetics, UMR 9002, CNRS and University of Montpellier, Montpellier, France.
Vincent L; Clinical Proteomic Platform, CHU Montpellier, Montpellier, France.
Grandmougin C; Institute of Human Genetics, UMR 9002, CNRS and University of Montpellier, Montpellier, France.
Seckinger A; Department of Clinical Hematology, CHU Montpellier, Montpellier, France.
Goldschmidt H; Institute of Human Genetics, UMR 9002, CNRS and University of Montpellier, Montpellier, France.
Constantinou A; Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Pasero P; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany.
Hose D; Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Moreaux J; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany.

Leukemia ; 31(10): 2104-2113, 2017 10.

Article en En | MEDLINE | ID: mdl-28186131

RESUMEN

Multiple myeloma (MM) is a plasma cell cancer with poor survival, characterized by the expansion of multiple myeloma cells (MMCs) in the bone marrow. Using a microarray-based genome-wide screen for genes responding to DNA methyltransferases (DNMT) inhibition in MM cells, we identified RECQ1 among the most downregulated genes. RecQ helicases are DNA unwinding enzymes involved in the maintenance of chromosome stability. Here we show that RECQ1 is significantly overexpressed in MMCs compared to normal plasma cells and that increased RECQ1 expression is associated with poor prognosis in three independent cohorts of patients. Interestingly, RECQ1 knockdown inhibits cells growth and induces apoptosis in MMCs. Moreover, RECQ1 depletion promotes the development of DNA double-strand breaks, as evidenced by the formation of 53BP1 foci and the phosphorylation of ataxia-telangiectasia mutated (ATM) and histone variant H2A.X (H2AX). In contrast, RECQ1 overexpression protects MMCs from melphalan and bortezomib cytotoxicity. RECQ1 interacts with PARP1 in MMCs exposed to treatment and RECQ1 depletion sensitizes MMCs to poly(ADP-ribose) polymerase (PARP) inhibitor. DNMT inhibitor treatment results in RECQ1 downregulation through miR-203 deregulation in MMC. Altogether, these data suggest that association of DNA damaging agents and/or PARP inhibitors with DNMT inhibitors may represent a therapeutic approach in patients with high RECQ1 expression associated with a poor prognosis.

Asunto(s)

ADN de Neoplasias/genética; Resistencia a Antineoplásicos/fisiología; Mieloma Múltiple/enzimología; Proteínas de Neoplasias/fisiología; RecQ Helicasas/fisiología; Bortezomib/farmacología; Ciclo Celular/efectos de los fármacos; Roturas del ADN de Doble Cadena; Daño del ADN; Metilación de ADN/efectos de los fármacos; Replicación del ADN/efectos de los fármacos; ADN de Neoplasias/metabolismo; ADN-Citosina Metilasas/antagonistas & inhibidores; Inducción Enzimática; Inhibidores Enzimáticos/farmacología; Inhibidores Enzimáticos/uso terapéutico; Regulación Neoplásica de la Expresión Génica; Humanos; Melfalán/farmacología; MicroARNs/genética; Terapia Molecular Dirigida; Mieloma Múltiple/tratamiento farmacológico; Mieloma Múltiple/genética; Mieloma Múltiple/patología; Proteínas de Neoplasias/antagonistas & inhibidores; Proteínas de Neoplasias/genética; Células Madre Neoplásicas/efectos de los fármacos; Células Madre Neoplásicas/enzimología; Células Plasmáticas/efectos de los fármacos; Células Plasmáticas/enzimología; Poli(ADP-Ribosa) Polimerasa-1/metabolismo; Interferencia de ARN; ARN Interferente Pequeño/genética; RecQ Helicasas/antagonistas & inhibidores; RecQ Helicasas/genética; Células Tumorales Cultivadas

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ADN de Neoplasias / Resistencia a Antineoplásicos / RecQ Helicasas / Mieloma Múltiple / Proteínas de Neoplasias Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google